PARAMUS, N.J., October 30, 2019 – PGI Drug Discovery LLC (PsychoGenics), announced today that it has received milestone payments from Sunovion Pharmaceuticals Inc. (Sunovion) associated with the advancement of two compounds into clinical testing – SEP-378614 and SEP-380135, bringing the total to four compounds now being studied in clinical trials for people living with neuropsychiatric conditions.